Fjarde AP Fonden Fourth Swedish National Pension Fund Boosts Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 74.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,830 shares of the medical research company’s stock after purchasing an additional 4,200 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Charles River Laboratories International were worth $1,815,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Versant Capital Management Inc raised its position in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the period. Assetmark Inc. grew its stake in shares of Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. grew its stake in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Charles River Laboratories International in the third quarter valued at $59,000. Finally, ORG Wealth Partners LLC acquired a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $56,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In other news, COO Birgit Girshick bought 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was acquired at an average cost of $164.63 per share, with a total value of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Up 0.6 %

NYSE:CRL opened at $168.07 on Thursday. The stock has a 50-day simple moving average of $171.70 and a 200-day simple moving average of $187.41. The stock has a market cap of $8.59 billion, a P/E ratio of 1,120.48, a P/E/G ratio of 4.54 and a beta of 1.37. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $275.00. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.46 EPS. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CRL has been the subject of a number of research reports. Evercore ISI lifted their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research note on Thursday, November 7th. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective for the company. in a research note on Monday, November 18th. The Goldman Sachs Group dropped their price objective on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. UBS Group reaffirmed a “neutral” rating and issued a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Finally, Robert W. Baird lowered their target price on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $195.71.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).